Miami Beach walking tour down Ocean Drive during Spring Break. We walk around and compare 2021 spring break and 2022 spring break. Things seem much more controlled and movement within south beach seems more normal. Miami Beach Police were making sure all visitors were safe and having a great time. My name is Alfred Montaner […]
The post Spring Break Miami Beach 2022 ! (Ocean Drive Walking Tour ) first appeared on Miami In News.
Detectives seized millions of dollars of drugs along with guns and cash and arrested 85 suspects accused in an international drug smuggling operation. FOX 13 Tampa Bay brings you the important videos like breaking news, Tampa Bay weather, and local stories. But also plenty of fun stuff, like ‘We Live Here’ tips, the best of […]
THE NEW STUDIO ALBUM “NOBODY’S FOOL” WILL RELEASE OCTOBER 28th BY KTBA RECORDS AVAILABLE ON CD, VINYL AND DIGITAL BOCA RATON, FL, UNITED STATES, September 28, 2022 /EINPresswire.com/ — Today, Joanne Shaw Taylor releases “Fade Away,” the next breathtaking single taken from her forthcoming breakthrough studio album Nobody’s Fool. The single can be streamed here. […]
New line of mushroom-powered gummies targets creating quick natural health benefits in the daily routine.
Troomy Mushroom Gummies
…
In 2022 Mazda remains as elegant as ever and keeps the fabled Japanese reliability. Today we will cover their latest car lineup that now includes some worthy crossover SUVs. Join us on this informative journey with #AutomotiveTerritoryDailyNews. #1 2023 Mazda CX-60 2023 Mazda CX-60 is the first plug-in hybrid SUV from the brand that belongs […]
Dr. Korb Dr. Korb with her dogs, Charlie and Tucker
CHARLESTON, S.C. – October 11, 2022 – (Newswire.com)
…
Ambit to showcase its prevalence projection approach, co-developed with Praxis, for rare developmental and epileptic encephalopathies (DEEs) as a Platform Presentation at this year’s annual Child Neurology Society meeting
CINCINNATI – October 11, 2022 – (Newswire.com)
Ambit®, a data and technology-enabled biopharma services company, today announced that leadership will debut Ambit’s data-driven methodology for projecting prevalence and diagnosis rates for difficult-to-quantify DEEs at the 51st Annual Child Neurology Society Meeting on Oct. 13, 2022. Ambit’s analytics team has developed this methodology in collaboration with Praxis Precision Medicines, Inc. (NASDAQ: PRAX) and the UCSF Weill Institute for Neurosciences and Benioff Children’s Hospitals.
For many rare DEEs, reliable prevalence estimates are not available. With a robust and growing pipeline of precision medicine therapies in rare epilepsy and neurodevelopmental disorders, estimating the prevalence of these conditions with a data-driven methodology can be highly valuable to drug developers, medical device companies and other healthcare decision-makers.
“Ambit’s expertise in a data-driven approach to prevalence projections for rare neurological conditions has allowed Praxis to characterize DEE populations with a high degree of confidence,” said Marcio Souza, president and chief executive officer of Praxis. “As we seek to bring first-in-class, potentially disease-modifying therapies to DEE patients in need, our collaboration with Ambit has been invaluable in increasing our understanding of these patient groups.”
Despite the availability of sponsored genetic testing and increased awareness of the benefit of genetic testing, over 50% of patients with rare DEEs remain undiagnosed. Sizing these patient populations and diagnosis rates underscores the importance of earlier genetic testing for unexplained seizure disorders and rare DEEs. “Even today, the path to accurate diagnosis and appropriate care for rare genetic epilepsies can be long and full of challenges,” said Adam Numis, M.D., of the UCSF Benioff Children’s Hospital. “Ambit’s methodology underscores the need for more treatment options to improve outcomes and quality of life for the rare DEE population.”
Ambit chief executive officer, Robert Sederman, will present this methodology on Oct. 13 as part of the Platform II Presentation Session (PL2-1) at the 2022 Annual Child Neurology Society Meeting. Presentations will run from 7-9 a.m. ET in the Junior Ballroom CD at the Duke Energy Center. Ambit will be presenting from 7-7:15 a.m. The associated abstract will be published in a supplement to the October issue of Annals of Neurology.
“We are excited to partner with Praxis and UCSF to showcase Ambit’s DEE projection methodology at this year’s meeting and, ultimately, see the impact of this collaboration on greater access to accurate diagnosis and treatment for patients with rare DEEs in the future,” said Sederman.
About Ambit Inc.
Ambit Inc.® is a data and technology-enabled biopharma and healthcare services company with a focus on rare and specialty disease. Ambit’s patient identification services drive patient activation and earlier diagnosis for patients that may be suffering from rare diseases. Ambit’s analytics and professional services support rare and specialty biopharma across the clinical development and commercialization of potentially life-changing therapies. To learn more about Ambit’s DEE Projection approach and other capabilities, please reach out to inquiries@ambitinc.com.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying insights from genetic epilepsies to both rare and more prevalent neurological disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio with multiple programs, including product candidates across movement disorders, epilepsy and psychiatric disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on LinkedIn and Twitter.
Contact Information:
Alexis Burbank
Marketing, Ambit Inc.
Press Release Service
by
Newswire.com
Tuffy Tire & Auto Service recommends AutoVitals software solutions across their network of over 160 locations.
AutoVitals AutoVitals Logo
…
CEV’s patent has positioned the company to make great strides by leveraging its intellectual property to make vehicle electrification more affordable and scalable
AUSTIN, Texas – October 11, 2022 – (Newswire.com)
Current EV Motors LLC (CEV), an Austin, Texas-based vehicle electrification company, announced today that the United States Patent and Trademark Office (USPTO) issued a patent covering the application of three different “direct drive” platforms that simplify the vehicle electrification process.
ABOUT THE PATENT
The USPTO issued U.S. Patent No. 11351850B1, entitled “Universal Electric Conversion Kit for Internal Combustion Vehicles” (“the patent”), which demonstrates that through the right balance of gearing, weight calculations, vehicle dynamics, and appropriate use of battery and motor technology, a vehicle’s old transmission may be eliminated and direct drive may be implemented — optimizing the vehicle’s energy usage. CEV’s platforms based on these designs allow for a more efficient drivetrain and a faster install time, allowing EV retrofits for consumers and fleets to scale much more rapidly than traditional customer retrofits.
ABOUT CURRENT EV MOTORS
CEV was founded to simplify and scale the conversion of internal combustion vehicles to electric drive, enabling the cost-effective conversion of the world’s existing vehicle population. The founders recognized that the trends of increased classic vehicle ownership, demand for consumer and fleet vehicle electrification, and rapid development of electrification technology could be brought together in a cost-effective manner via direct drive designs. The company develops and produces kits that regional shops can install in consumer and fleet vehicles. CEV plans to open a facility in 2023 where the company will install these solutions in vehicle chassis with speed and at scale.
For media inquiries, please contact media@currentevmotors.com.
For investor inquiries, please contact ir@currentevmotors.com.
Contact Information:
Rocco Calandruccio
CEO
5125744791
Press Release Service
by
Newswire.com
Original Source:
Current EV Motors (CEV) Announces Patent Granted by USPTO
The American Academy of Stem Cell Physicians will be hosting its fall Scientific Congress in Chicago, IL, on Oct. 28, 2022.
AASCP Chicago lecture …